Bupropion
An antidepressant and smoking cessation aid that inhibits the reuptake of norepinephrine and dopamine in the brain. It is used to treat major depressive disorder, seasonal affective disorder, and to help people quit smoking. Unlike many antidepressants, it does not typically cause sexual dysfunction or weight gain, and is associated with a dose-dependent risk of seizures.
分子量
239.7420 g/mol
LogP
3.20
TPSA
29.10 Ų
Lipinski 五规则
符合
治疗领域
药物分类
作用机制
Norepinephrine-dopamine reuptake inhibitor (NDRI).
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Norepinephrine-dopamine reuptake inhibitor (NDRI).
二维结构
Cite this structure
Embed this structure
SMILES
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
InChI
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
Molecular Formula
C13H18ClNO
HBD / HBA
1 / 2
可旋转键数
4
重原子数
16
Bupropion combined with tramadol increases the risk of both serotonin syndrome and seizures, representing a serious dual-hazard drug combination.
Bupropion inhibits CYP2D6, significantly increasing venlafaxine plasma concentrations, which may enhance both therapeutic and adverse serotonergic effects.
Bupropion inhibits CYP2D6, modestly increasing quetiapine levels, while also lowering the seizure threshold — both risks are additive.
Bupropion is a potent CYP2D6 inhibitor that substantially increases metoprolol plasma concentrations, potentially causing excessive beta-blockade (bradycardia, hypotension, heart block).
Bupropion, a CYP2D6 inhibitor, significantly increases aripiprazole plasma concentrations, increasing the risk of dose-dependent adverse effects.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
An antidepressant and smoking cessation aid that inhibits the reuptake of norepinephrine and dopamine in the brain. It is used to treat major depressive disorder, seasonal affective disorder, and to help people quit smoking. Unlike many antidepressants, it does not typically cause sexual dysfunction or weight gain, and is associated with a dose-dependent risk of seizures.
Norepinephrine-dopamine reuptake inhibitor (NDRI).
Key pharmacokinetic parameters for Bupropion: Half-life: 21 hours.
Yes, Bupropion is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL894. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 444. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bupropion"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bupropion/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bupropion/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bupropion/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bupropion"></drugfyi-drug>